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Aim: Pulmonary vein thrombi (PVT) are believed to be rare. Some cases of PVT were reported in patients with
lung cancer, thoracic surgery or catheter ablation. PVT are a possible cause of systemic embolism, but little is
known about its complications. Since 2012, we have reported seven cases of PVT in patients without these pre-
disposing factors.
The aim of the present study was to clarify whether PVT were rare or not in patients without these predisposing
factors and how can we treat patients with PVT.
Methods: We performed 64-slice multidetector CT (64-MDCT) scans on 57 consecutive Japanese patients (28
men and 29women; age= 73.8± 8.6 years old) with chest pain, but they didn't have lung cancer, thoracic sur-
gery or catheter ablation, from September 2012 to March 2013.
Results: Coronary artery plaque was detected in 32 patients (56%). PVTwere clearly demonstrated in 35 patients
(61%), which indicated that PVT are not rare. Furthermore, 32 patients (91%) among 35 patients with PVT had no
cerebral infarctions. In older people, PVT are not uncommon and have many clinico-pathologic correlations.
Small or ﬁne thrombi in the pulmonary vein should occlude a small artery of every organ and make effects on
many diseases, which are not recognized by almost all medical doctors.
Conclusions: PVT are common observation in patients with chest pain and no clear predisposing factor. Further
studies are required to assess if PVT can be considered as an etiology of chest pain and to determine its optimal
management.
© 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Pulmonary vein thrombi (PVT) are believed to be rare, and they are
not generally recognized as a cause of systemic thrombosis such as is-
chemic stroke and acute myocardial infarction. Although PVT was re-
ported to have no association to ischemic stroke [1], we think that PVT
are potentially life-threatening condition and cause ischemic stroke
like other cardiac thrombi such as left atrial appendage thrombi and
left atrial thrombi [2,3]. More than 15% of embolic strokes are reported
to be associated with cardiac thrombi, and the left atrial appendage is
believed as the most predisposed location [4,5].
PVT have been reported to be associated with lung cancer [6,7], lung
surgery [8–10] and radiofrequency catheter ablation [11,12]. Since
2012, we have reported seven cases of PVT in patients without such pre-
disposing factors on cardiac CT scans using a 64-slice multidetector CT
(64-MDCT) [13–20]. The quality of these images has been good, and oneThis is an open access article under tof them was linked to thrombi in the left antrum that could be demon-
strated by transthoracic echocardiography (TTE) [16]. These data showed
that 64-MDCT and TTE can illustrate thrombi clearly and noninvasively.
The useful therapy for PVTmanagement is treatment with anticoagu-
lants, such as warfarin and dabigatran. Recently, dabigatran has been re-
ported to be effective for stroke prevention and to have a lower bleeding
risk compared to warfarin [21]. Although antibiotics were used in earlier
cases, they lack a proven rolewhen the PVT are not associatedwith infec-
tion [22,23]. If lung infarction is suspected because of a severe clinical sta-
tus, then embolectomy or lobe resection may be indicated [22,24].
The aim of the present studywas to clarifywhether PVTwere rare or
not in patients with chest pain, but they didn't have these predisposing
factors and whether dabigatran dissolved PVT or not.2. Methods
2.1. Study population
We retrospectively reviewed the 64-MDCT scans of 57 consecutive
Japanese patients (28 men and 29 women; age = 73.8 ± 8.6 yearshe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Japan, fromSeptember 2012 toMarch 2013.We assessed the data retro-
spectively. These patients had no evidence of lung cancer, lung surgery
or radiofrequency catheter ablation. Biochemical screening tests, such
as total bilirubin, were examined using traditional methods within
two weeks before the 64-MDCT scans. This study was retrospective
study, so ethical committee approval was not obtained. Patient consent
was not obtained but the presented data are anonymized and risk of
identiﬁcation is low.
2.2. 64-MDCT scan procedures
The patients were examined using 64-MDCTwithin onemonth after
onset of chest discomforts such as chest pain inmany cases. The patients
were connected to electrocardiogram (ECG) leads and placed in the su-
pine position to enable CT and ECG synchronization. The subjects
underwent 64-MDCT angiography as a traditional method. All of the
64-MDCT scanswere performedwith a 64-detector rowCT (Aquilion64,
Toshiba, Tokyo, Japan). Individuals presenting with baseline heart rates
(65 bpm) within 1 h prior to a 64-MDCT scan were administered oral
beta-blocker (metoprolol 20 mg) therapy to slow the heart rate. High
baseline heart rates make the quality of images worse. Nitroglycerin
0.3 mg sublingual was administered immediately prior to contrast
injection. The images were obtained during single breath-holds. Non-
ionic contrast (Omnipaque300 syringe 80 mL, Iohexol, Daiichi-
Sankyo) was administered into an antecubital vein via a dual-head in-
jector at a dose of 0.07 mL/kg × body weight (kg) per second (mL/s)
to 5.0 mL/s over 14 s in all of the cases. The scan volume included the
area under the bifurcatio tracheae region to the heart base and the
upper abdomen. For scanning in the craniocaudal direction, collimation
of 32.0 mmwas used at a rotation time of 0.35 s. The detector scan area
was 32.0 mm2. The thickness was 0.5 mm, the tube voltage was 135 kV
and the effective current was 440 mA. The slice thickness of the recon-
struction was 0.5 mm. Automatic triggering with a region of interest at
the descending aorta (a threshold of 150 HU)was used. After scan com-
pletion, the 64-MDCT scanswere reconstructed using retrospective ECG
triggering. Axial slices were reconstructed using an ECG-gated half-scan
reconstruction algorithm. Numerous phases were reconstructed within
the cardiac cycle to optimize structural visualizationwithoutmotion ar-
tifacts. PVT images were obtained at the same time when 64-MDCT
scans were examined to assess coronary artery stenosis. If we had
changed the conditions of scans for getting PVT images, then PVT
might have been identiﬁed in more cases. We deﬁned a pulmonary
vein thrombus as a clear defect of contrast enhancements in the pulmo-
nary vein. If an unclear defect in the pulmonary vein was identiﬁed, we
deﬁned it as no thrombus in the pulmonary vein; consequently, the rate
of thrombus might be underestimated in this paper, and there is a pos-
sibility that more patients had PVT than we report here. Because PVT
could not be clearly deﬁned here, it is difﬁcult to compare the two
groups (patients with PVT versus patients without PVT) because some
of the patients in the group deﬁned as without PVT might have actually
had PVT.
3. Statistical analysis
The distribution of the continuous variables was determined using
the Kolmogorov–Smirnov test. Continuous variableswith normal distri-
butions were summarized as the means ± standard deviations (SD) or
numbers (percentages). The difference between the means of the two
independent groups was calculated using Student's t test, which was
also used to compare the values of patients with PVT to the values of
patients without PVT. For all statistics, a two-sided p value b0.05 was
considered statistically signiﬁcant. The data were analyzed using com-
mercially available XLSTAT statistical software (Version 2013.4,
Addinsoft).4. Results
4.1. Patients with PVT vs. patients without PVT
Coronary artery plaquewas observed in 32 patients (56%). PVTwere
clearly identiﬁed in 35 patients (61%). The mean age of the 35 patients
with PVT was 75.3 ± 7.2 years (19 men and 16 women; range: 60
to 88 years), and the mean age of the 22 patients without PVT was
71.4 ± 10.2 years (9 men and 13 women; range: 43 to 89 years).
The difference in mean age between the two groups was not signiﬁ-
cant (p = 0.097). The 33 patients with PVT were treated with
dabigatran, and the 2 patients with PVT were treated with warfarin
because they experienced dyspepsia after taking dabigatran.4.2. Laboratory data
The laboratory investigation revealed that the mean total bilirubin
value (normal range: 0.3–1.1 mg/dL) of the 35 patients with PVT was
0.72 ± 0.52 mg/dL (range: 0.3 to 2.8 mg/dL), and 9 of these patients
had values N0.08 mg/dL. Furthermore, the mean total bilirubin values
of the 22 patients without PVT was 0.51 ± 0.18 mg/dL (range: 0.3–
0.8 mg/dL), with no values N0.08 mg/dL. The difference in mean total
bilirubin between the two groups was not signiﬁcant (p= 0.074), and
the mean values for glutamic-oxaloacetic transaminase (normal
range; 10–40 IU/L) and glutamic-pyruvic transaminase (normal range
5–40 IU/L) in the 35 patients with PVT were 28.7 IU/L and 22.0 IU/L,
respectively; none of the 22 patients without PVT exhibited any signif-
icant differences between these factors (28.2 IU/L and 25.0 IU/L, respec-
tively). In addition, among the 35 patients with PVT, the D-dimer
serum levels were examined in 23 patients. The mean D-dimer
value was 0.72 ± 0.72 μg/mL. Among these patients, six (26%) had
values greater than 1.0 μg/mL (normal range: b1.0 μg/mL); the mean
D-dimer value was 1.59 ± 0.69 μg/mL, and the highest level was
2.9 μg/mL.4.3. Dabigatran therapy
At the same day of 64-MDCT scan examination, patients were
started to be treated with anticoagulants if PVT were identiﬁed. After
3 months of dabigatran (33) or warfarin (2) treatment, only one of
the 35 patients with PVT presented PVT that had dissolved almost
entirely [19], and some of PVT dissolved partially [20], but others of
PVT did not dissolve signiﬁcantly. Among the PVT patients, 3 had cere-
bral infarctions, and 1 patient with atrial ﬁbrillation (AF) and 1 patient
with paroxysmal atrial ﬁbrillation (pAF) did not experience cerebral
infarction. During and after the treatment, chest pain and cerebral in-
farction occurs in no patients and the patients felt better.5. Discussion
5.1. Findigs
In this manuscript, we show that some elderly patients with chest
pain have PVT, as assessed using a 64-MDCT scan, and that these PVT
were difﬁcult to dissolve with 3 months of warfarin or dabigatran
treatment.
The novel ﬁndings of this study were that PVT are not rare in elderly
patients with chest pain and that PVTmay be common in older individ-
uals. In this study, the timing of getting PVT images is adjusted to get the
best images coronary artery plaque and our deﬁnition of a thrombus in
the pulmonary vein tended to underestimate the number of patients






Fig. 1. A 64-MDCT scanwith contrast enhancement of the ﬁrst patient revealed a left lower pulmonary vein thrombus (yellow arrowhead) as the defect. The red arrowhead indicated the
left atrial appendage. A; axial, B; coronal, and C; sagittal. LA = left antrum.
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The present results indicated that many elderly patients with chest
pain had PVT (61%), which is an original and very important ﬁnding be-
cause both left atrial appendage thrombi [2–5] and PVT can cause ische-
mic stroke. Grau et al. reported that younger cryptogenic stroke patients
(average age; 48 years old) have no PVT as assessed usingmagnetic res-
onance angiography [1]. Such younger patients seem not to have PVT.
PVT can cause hemodynamic changes. Co-lateral venous vesselsmay
be developed like deep venous thrombosis such as femoral venous
thrombosis. Our images showed no co-lateral venous vessels around
proximal pulmonary veins, but there may be co-lateral around distal
pulmonary veins. Our images showed rather enlarged (less than about
2.5 cm) pulmonary vein, indicating that pulmonary veins become larger
to compensate pulmonary vein ﬂow in occluded pulmonary vein. (The
normal size of pulmonary vein is about 1 cm.) It is unknown whether
these changes can cause chest pain or not.
Although the current ﬁndings indicated that anticoagulants had
some effects on thrombi as assessed using 64-MDCT, the decision to
use anticoagulants is not a simple matter. Because the identiﬁcation of
very small thrombi using 64-MDCT or TTE is difﬁcult, dabigatran may
be beneﬁcial for dissolving not only the detected ﬂoating thrombi [19]
but also undetected ﬁne thrombi. At the very least, the new oral anti-
coagulants appear to be more effective than warfarin for patients with
AF [21].
Furthermore, the patients with PVT in this study exhibited a trend
towards higher total bilirubin, indicating that total bilirubin may be an
effective biomarker for PVT. However, why total bilirubin was elevated
in some patients with PVT remains unknown.
According to these results, the serum D-dimer levels of the patients
with PVT were not high. Among the 23 patients with DVT whose
D-dimer levels were examined, 17 patients (74%)were within the nor-
mal range, indicating that the existence of PVT does not necessarilyD E
LA
LA
Fig. 2. A 64-MDCT scan of the ﬁrst patient demonstrated that the left lower pulmonary vein t
(150 mg twice daily), suggesting that the pulmonary vein thrombus had been dissolved to so
image of the left atrial appendage (red arrowhead). D; axial, E; coronal, and F; sagittal. LA = leraise the serum level of D-dimer. If the serum D-dimer level is not
elevated, it does not necessarily indicate that there are no PVT.
Therefore, when 64-MDCT scans are administered to patients who
complain of chest pain, screening for PVT should be performed to pre-
vent systemic thrombosis, such as ischemic stroke. It is important that
we recognize that PVT can not cause ischemic stroke so easily. Only 3
patients with PVT had ischemic stroke among 35 patients with PVT.
PVT may be too stable to cause ischemic stroke easily, but PVT can
cause ischemic stroke in some cases, so it is important to make effects
on PVT.
Moreover, recognizing that 64-MDCT can reliably identify PVT is
important, and a left atrial thrombus can typically be detected semi-
invasively using transoesophageal echocardiography. However, it is
difﬁcult to diagnose PVT correctly, and PVT are currently not well recog-
nized. The following new example cases illustrate this clinical situation.
First, a 73-year-old male presented hypertension but no AF or cerebral
infarction. The 64-MDCT revealed a thrombus in the left lower pulmo-
nary vein (Fig. 1), and after 3 months of dabigatran therapy (150 mg
twice daily), some parts of the thrombus were remained but had be-
come smaller and less discernible (Fig. 2). Second, an 82-year-old
male presented with hypertension and transient ischemic attacks but
no AF. The 64-MDCT revealed a thrombus in the left lower pulmonary
vein (Fig. 3), and after 3 months of dabigatran therapy (110 mg twice
daily), the thrombus remained present but had become rather small
and less discernible (Fig. 4).
Small or large pulmonary veins that are completely occluded present
another important biological problem. Essentially, arterial blood ﬂows
into the pulmonary vein, which is rich in oxygen and nutrients. Howev-
er, the arterial blood cannot ﬂow into an occluded pulmonary vein,
which causes pulmonary vein hypoxia and undernourishment and acti-
vates hypoxia-inducible factors (HIFs) and other transcription factors,
such as nuclear respiratory factor-1 (NRF-1), cyclic-AMP response
element-binding protein (CREB) and metal-responsive transcriptionF
LA
hrombus had become unclear (yellow arrowhead) after 3 months of dabigatran therapy






Fig. 3. A 64-MDCT scan with contrast enhancement of the second patient revealed a left upper pulmonary vein thrombus (yellow arrowhead) as the defect. The red arrowhead indicated
the left atrial appendage. G; axial, H; coronal, and I; sagittal. LA = left antrum.
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human diseases, including cancer, diabetes and ischemic cardiovascular
disease [25]. Additionally, HIFs play crucial roles in embryonic develop-
ment, postnatal physiology and disease pathogenesis [26–31]. HIFs have
also been shown to affect epigenetic reprogramming [32,33], cancer [34],
embryonic stem (ES) cells [35–37] and angiogenesis [38,39], leading to
the formation of hemangioblast precursor cells [40]. These factors can
also induce the pulmonary vein myocardium to produce and maintain
AF. Although 35 patients in this study had PVT, 1 patient had AF and 1 pa-
tient had pAF, indicating that PVT precedes AF. Because patients with PVT
orAF are often elderly, the incidences of both PVT andAF increasewith age.
PVT can have important clinical implications for many organs and
the size and number of PVT designate the speciﬁc effects on other or-
gans. First, large chips of PVT can cause acute systemic thrombosis,
such as acute cerebral infarction and acute myocardial infarction
(AMI). Approximately 70% of patients with AMI have coronary artery
stenosis of less than 50% [41,42], and the rupture of coronary artery ath-
erosclerotic plaques resulting in occlusion is considered an important
precipitating step of AMI. Acute coronary syndromes are thought to re-
sult from the rupture of vulnerable plaques, which are believed to be
moderately stenosed and not visible by conventional angiography. In
addition, other acute coronary syndromesmaybe caused bymoderately
sized occlusions of the coronary artery and moderately sized PVT. Sec-
ondly,manyﬁne or small tips of PVT can chronically occlude the arteries
of all organs, resulting in limited oxygen and nourishment to various or-
gans. Cells within these organs may have to adapt (transform) to sur-
vive under such abnormal circumstances by changing their expression
of proteins associated with activated transcription factors, such as
HIFs, CREB, NRF-1 andMTF-1, or by undergoing epigeneticmodulations,
such as histone acetylations and DNA methylations.J K
LA
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Fig. 4.A64-MDCT scan of the secondpatient revealed that the left upper pulmonary vein thromb
(150 mg twice daily), suggesting that the pulmonary vein thrombus had dissolved to some ext
image of the left atrial appendage (red arrowhead). J; axial, K; coronal, and L; sagittal. LA = leApproximately 10–20% of patients with typical angina pectoris have
normal coronary arteries, and most of these patients are classiﬁed as
syndrome X [43,44]. However, syndrome X represents a heterogeneous
group that includes slow coronaryﬂow(SCF) [45], an angiographicﬁnd-
ing characterized by the late opaciﬁcation of the epicardial coronary
arteries without the presence of occlusive coronary disease [46]. The
etiopathogenesis of SCF is not yet fully understood, although occlusive
disease of the small coronary arteries has been suggested as a cause
[47]. In addition, many ﬁne or small tips of PVTmay chronically occlude
the small coronary artery, which can cause SCF.
Epicardial adipose tissue (EAT) is supplied by small side-branches of
the coronary arteries similar to themicrocirculation of themyocardium.
EAT was reported to modulate both myocardium and coronary arteries
locally [48]. Fine or small thrombi of PVT may occlude the small coro-
nary arteries, which can cause chronic heart failure and coronary artery
atherosclerosis.
The occlusion of other arteries in other organs may cause cancer via
hypoxia and under-nourishment, asmany cancers and stem/progenitor
cells can continue proliferating under hypoxia [49,50]. Hypoxia main-
tains the undifferentiated cell state and regulates differentiation [36].
Cerebral hypoperfusion leading to hypoxia has been implicated as a cru-
cial underlying factor that promotes dementia [51,52]. Hypoxia triggers
a cascade of events that contribute to the pathologic processes of
Alzheimer's disease through the activation of multiple pathways [53,
54]. These changes associated with hypoxia and hypo-glucose states
may occur in not only cancer cells but also ischemic heart cells, EAT
cells or cerebral cells, and these events are typically the result of the
occlusion of arteries by ﬁne or small thrombi of PVT.
Although we recently reported that dabigatran dissolved ﬂoating
PVT [19,20], we report in this paper new two cases showing thatL
LA
us had become small andunclear (white arrowhead) after 3 months of dabigatran therapy
ent. The clarity of the images was almost same before and after therapy, judging from the
ft antrum.
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showing thatwarfarin dissolved PVT [14]. These treatments can prevent
aging-associated diseases such as AF, cancer, dementia, Alzheimer's dis-
ease and AMI by dissolving thrombi. Dissolving thrombi in pulmonary
veins or small arteries without inducing hypoxia and under-
nourishment would be beneﬁcial, which may have positive effects on
treatments such as chemotherapy. Moreover, because PVT may pro-
mote aging, the prevention and cure of PVTmay prevent certain aspects
of aging.
5.3. Limitations
The most important limitation was the deﬁnition of a pulmonary
vein thrombus. At present, the 64-MDCT scan seemed the bestmodality
for identifying a pulmonary vein thrombus. In some cases, we could see
vague defects; in those cases, we diagnosed no thrombus. We believe
that pulmonary vein thrombus may have existed in such cases. In
other words, there may be more patients with PVT than the results of
this study suggest. The statistical ﬁgures in this study had little signiﬁ-
cance because PVTmay have been underdiagnosed.We need to explore
more appropriate examinations to identify PVT more accurately.
And the cause of forming PVT is unclear in this study. Blood stasis
and hypercoagulability have been associated with the development of
venous thrombosis. According to our results, patients with PVT were
older than patients without PVT, and the lower activity levels of older
individuals could lead to decreased cardiac output, resulting in slowed
pulmonary vein blood ﬂow. Thus, such blood stasis could cause the for-
mation of PVT in older patients. In addition, the level of physical activity
could be more meaningful than age, and daily exercise, such as swim-
ming, jogging or walking, may help prevent PVT. More studies to clarify
the cause are required.
5.4. Clinical implications
Most elderly patients may have PVT. But many elderly people don't
complain chest pain. Some of patients with PVT complain chest pain,
when they make efforts or exercise. It is important to assess clinical rel-
evance of PVT, but it is not easy, presently. Some of embolic strokes are
reported to be associated with cardiac thrombi, and the left atrial ap-
pendage is believed as themost predisposed location [4,5].Whenwe as-
sess the cause of stroke, it would be better to check pulmonary vein
thrombi using 64-MDCT. Furthermore, PVT can release microclots, and
when we treat patients with chest pain, cancer and dementia, we
should assess PVT and take into account the effects of PVT. Additionally,
it is important to recognize that anticoagulants such as warfarin and
dabigatran could dissolve PVT, which suggests that anticoagulants pre-
vent ischemic stroke and cure or inhibit to exacerbate chest pain, cancer
and dementia. Physical activity has a possible therapy for such diseases.
5.5. Conclusions
In conclusion, among 57 patients with chest pain, 35 (61%) had PVT
as evaluatedusing 64-MDCT, indicating that PVT are not rare. The serum
level of total bilirubin could be a biomarker for PVT. 64-MDCT is a valu-
able tool for identifying PVT. Dabigatran orwarfarin therapy cannot dis-
solve PVT lesions very easily. A thrombus in the pulmonary vein can
cause hypoxia and undernourishment. More studies of this topic are
needed.
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